Pharmacy Search
Vertice Login
Menu
close

Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.
← Back to Medmonitor

Medication Type: Degenerative Conditions

Enoby™ (denosumab-qdbe) injection

Approval Date: Sep 2025

Note: Biosimilar

A biosimilar to Prolia®, this drug is a RANKL inhibitor indicated for the treatment of osteoporosis in postmenopausal women with high risk of fracture, to increase bone mass in men with osteoporosis at a high risk for fracture, for the treatment of glucocorticoid-induced osteoporosis in men and women with high risk of fracture, and more

Medication Name

Approval Date

Category

Description

Enoby™ (denosumab-qdbe) injection

Sep 2025

A biosimilar to Prolia®, this drug is a RANKL inhibitor indicated for the treatment of osteoporosis in postmenopausal women with high risk of fracture, to increase bone mass in men with osteoporosis at a high risk for fracture, for the treatment of glucocorticoid-induced osteoporosis in men and women with high risk of fracture, and more

Note: Biosimilar
lockenvelopephone-handsetmagnifiermenucross-circle